Small molecule · Inhibitor of isocitrate dehydrogenase 1 (mutant) (IDH1) and isocitrate dehydrogenase 2 (mutant) (IDH2) · developed by Hutchmed
Ranosidenib (HMPL-306) is an orally bioavailable small molecule that inhibits mutant forms of IDH1 and IDH2, blocking the formation of the oncometabolite 2-hydroxyglutarate from alpha-ketoglutarate. It is being studied in acute myeloid leukemia, IDH-mutant gliomas, and a mass balance study.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07912398 | Phase 3 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Not yet recruiting | HCM |
| NCT06387069 | Phase 3 | Acute Myeloid Leukemia | Recruiting | HCM |
| NCT07025018 | Phase 1 | Gliomas Harboring IDH1 and/or IDH2 Mutations | Recruiting | HCM |
| NCT06671873 | Phase 1 | Mass Balance Study | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaGliomas Harboring IDH1 and/or IDH2 MutationsMass Balance Study
Updated Nov 15, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →